Merck KGaAXSWX:MER +4.03%83 Pretax Margin % is 16.93% as of Mar. 2026, which is 10% above its 10-year median of 15.34. GuruFocus rates XSWX:MER with a GF Score™ of 83/100 and a GF Value™ of CHF125.76. The stock has 9 warning signs investors should review. Among 952 Drug Manufacturers companies, Merck KGaA ranks better than 71.11% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Merck KGaA's Pre-Tax Income for the
three
months ended in Mar. 2026 was CHF791 Mil. Merck KGaA's Revenue for the
three
months ended in Mar. 2026 was CHF4,673 Mil. Therefore, Merck KGaA's pretax margin for the quarter that ended in Mar. 2026 was 16.93%.
The historical rank and industry rank for Merck KGaA's Pretax Margin % or its related term are showing as below:
XSWX:MER'
s Pretax Margin % Range Over the Past 10 Years
Min: 9.85 Med: 15.34 Max: 19.93
Current: 15.37
XSWX:MER's Pretax Margin % is ranked better than 71.11% of 952
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs XSWX:MER: 15.37
Merck KGaA (XSWX:MER) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Merck KGaA Pretax Margin % Related Terms
Merck KGaA Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Merck KGaA's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:MER vs ZTS, UTHR, VTRS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Merck KGaA's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Merck KGaA Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Merck KGaA's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Merck KGaA's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merck KGaA (XSWX:MER) has a Pretax Margin % of 16.93% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Merck KGaA and its competitors. This is 10% above median its historical median of 15.34. Over the past decade, Merck KGaA's Pretax Margin % has ranged from 9.85 to 19.93. According to the industry distribution chart, Merck KGaA ranks #275 out of 952 companies in the Drug Manufacturers industry, placing it in the top 28.9%.
Is Merck KGaA's Pretax Margin % too high?
Merck KGaA's current Pretax Margin % of 16.93% is 10% above median its 10-year median of 15.34. Over the past 10 years, this metric has ranged from a low of 9.85 to a high of 19.93. The Drug Manufacturers industry median Pretax Margin % is 7.30. Merck KGaA's value of 16.93% is 132.1% above this industry median. Based on the distribution chart, Merck KGaA ranks #275 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Merck KGaA has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Merck KGaA ranks #275 out of 952 companies for Pretax Margin %. This puts Merck KGaA in the upper half of its industry. The industry median Pretax Margin % is 7.30. Merck KGaA's value of 16.93% is 132.1% above this benchmark. Historically, Merck KGaA's own Pretax Margin % has ranged from 9.85 to 19.93 over the past decade. While the company's 10-year median is 15.34 vs. the industry median of 7.30, Merck KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Merck KGaA's current Pretax Margin % of 16.93% is 132.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Merck KGaA and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Merck KGaA's current Pretax Margin % is 16.93%, which is 10% above median its own 10-year median of 15.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Merck KGaA (XSWX:MER) has a current Pretax Margin % of 16.93%. The stock's GF Value™ is CHF125.76, compared to a current price of CHF130.30 — trading 3.6% above its estimated fair value. The current Pretax Margin % is 16.93%, which is 10% above median its 10-year median of 15.34 and 132.1% above the Drug Manufacturers industry median of 7.30. Merck KGaA's overall GF Score™ is 83/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Merck KGaA (XSWX:MER), the current Pretax Margin % is 16.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Merck KGaA (XSWX:MER) Overvalued in 2026?
Based on GuruFocus' analysis, Merck KGaA stock appears to be overvalued.
The current stock price of CHF130.30 is trading 3.6% above its estimated GF Value™ of CHF125.76.
Key valuation signals for XSWX:MER:
Pretax Margin %: 16.93% (10% above median its 10-year median of 15.34)
GF Value™: CHF125.76 vs. price of CHF130.30 (3.6% above fair value)
Industry Position: 132.1% above the Drug Manufacturers median (#275 of 952)
No single metric tells the full story. See the XSWX:MER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
83GF Score
Get the complete analysis for XSWX:MER
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MER has been successfully added to your 
